Chang Jae C, Hawley H Bradford
Department of Medicine, University of California Irvine School of Medicine, Irvine, CA 92868, USA.
Department of Medicine, Wright State University Boonshoft School of Medicine, Dayton, OH 45435, USA.
Medicina (Kaunas). 2021 Oct 26;57(11):1163. doi: 10.3390/medicina57111163.
Serious vaccine-associated side effects are very rare. Major complications of vaccines are thrombocytopenia and thrombosis in which pathogenetic mechanism is consistent with endotheliopathy characterized by "attenuated" sepsis-like syndrome, leading to the activation of inflammatory and microthrombotic pathway. In the COVID-19 pandemic, acute respiratory distress syndrome caused by microthrombosis has been the major clinical phenotype from the viral sepsis in association with endotheliopathy-associated vascular microthrombotic disease (EA-VMTD), sometimes presenting with thrombotic thrombocytopenic purpura (TTP)-like syndrome. Often, venous thromboembolism has coexisted due to additional vascular injury. In contrast, clinical phenotypes of vaccine complication have included "silent" immune thrombocytopenic purpura (ITP-like syndrome), multiorgan inflammatory syndrome, and deep venous thrombosis (DVT), cerebral venous sinus thrombosis (CVST) in particular. These findings are consistent with venous (v) EA-VMTD. In vEA-VMTD promoted by activated complement system following vaccination, "consumptive" thrombocytopenia develops as ITP-like syndrome due to activated unusually large von Willebrand factor (ULVWF) path of hemostasis via microthrombogenesis. Thus, the pathologic phenotype of ITP-like syndrome is venous microthrombosis. Myocarditis/pericarditis and other rare cases of inflammatory organ syndrome are promoted by inflammatory cytokines released from activated inflammatory pathway, leading to various organ endotheliitis. Vaccine-associated CVST is a form of venous combined "micro-macrothrombosis" composed of binary components of "microthrombi strings" from vEA-VMTD and "fibrin meshes" from vaccine-unrelated incidental vascular injury perhaps such as unreported head trauma. This mechanism is identified based on "two-path unifying theory" of in vivo hemostasis. Venous combined micro-macrothrombosis due to vaccine is much more serious thrombosis than isolated distal DVT made of macrothrombus. This paradigm changing novel concept of combined micro-macrothrombosis implies the need of combined therapy of a complement inhibitor and anticoagulant for CVST and other complex forms of DVT.
严重的疫苗相关副作用非常罕见。疫苗的主要并发症是血小板减少症和血栓形成,其发病机制与以内皮病变为特征的“减轻型”败血症样综合征一致,导致炎症和微血栓形成途径的激活。在新冠疫情期间,由微血栓形成引起的急性呼吸窘迫综合征一直是与内皮病变相关的血管微血栓形成疾病(EA-VMTD)导致的病毒败血症的主要临床表型,有时表现为血栓性血小板减少性紫癜(TTP)样综合征。通常,由于额外的血管损伤,静脉血栓栓塞也会同时存在。相比之下,疫苗并发症的临床表型包括“无症状”免疫性血小板减少性紫癜(ITP样综合征)、多器官炎症综合征以及深静脉血栓形成(DVT),尤其是脑静脉窦血栓形成(CVST)。这些发现与静脉型(v)EA-VMTD一致。在疫苗接种后由激活的补体系统促进的vEA-VMTD中,由于通过微血栓形成激活了异常大的血管性血友病因子(ULVWF)止血途径,会出现类似ITP综合征的“消耗性”血小板减少症。因此,ITP样综合征的病理表型是静脉微血栓形成。心肌炎/心包炎以及其他罕见的炎症性器官综合征病例是由激活的炎症途径释放的炎症细胞因子所促进,导致各种器官的内皮炎症。疫苗相关的CVST是一种静脉型“微-大血栓形成”形式,由vEA-VMTD的“微血栓串”和可能如未报告的头部外伤等与疫苗无关的偶然血管损伤的“纤维蛋白网”这两个二元成分组成。这种机制是基于体内止血的“双途径统一理论”确定的。疫苗导致的静脉型微-大血栓形成比由大血栓构成的孤立远端DVT严重得多。这种改变范式的微-大血栓形成新概念意味着对于CVST和其他复杂形式的DVT需要联合使用补体抑制剂和抗凝剂进行治疗。